4 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 4, Unknown 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Dysentery: new trials by email Literature Review of Dysentery trials Research Report on Dysentery
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine S. Flexneri-S. Sonnei bivalent conjugate vaccine, Placebo - Dysentery, Dysentery, Shigella | Phase 3 | Active not recruiting | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 8000 | 2025-05-12 | 2026-04-01 |
| VE303 for Prevention of Recurrent Clostridioides Difficile Infection VE303, Placebo - Clostridium Difficile, Clostridium Difficile Infections | Phase 3 | Recruiting | Vedanta Biosciences, Inc. | 852 | 2024-05-20 | 2026-11-02 |
| GastroIntestinal Panel in Kidney Transplant Patients FilmArray GI - Kidney Transplant; Complications, Diarrhoea;Acute | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 135 | 2023-02-01 | 2023-02-22 |
| Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine, Placebo - Dysentery, Shigellosis | Phase 3 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 21000 | 2021-12-11 | 2022-01-11 |
| Efficacy of Rifaximin in Preventing Campylobacteriosis Rifaximin intervention, Placebo intervention - Dysentery, Diarrhea | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 30 | 2014-10-01 | 2018-11-20 |
| A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea GT267-004 (tolevamer potassium sodium) - Enterocolitis, Pseudomembranous, Diarrhea | Phase 3 | Terminated | Genzyme, a Sanofi Company | 65 | 2007-04-01 | 2015-03-19 |
| Rifaximin for Prevention of Travellers' Diarrhea Rifaximin, Placebo - Diarrhea | Phase 3 | Completed | Bausch Health Americas, Inc. | 210 | 2005-06-01 | 2019-12-18 |
| Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Shigella conjugate vaccines - Shigellosis | Phase 3 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2799 | 2003-01-01 | 2012-06-22 |
| Zinc Supplementation in Shigella Patients Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks. - Testing Effect of Intervention | Phase 3 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 56 | 1999-01-01 | 2006-05-03 |
Dysentery, Bacillary (5) · Diarrhea (3) · Campylobacter Infections (1) · Clostridium Infections (1) · Enterocolitis, Pseudomembranous (1) · Escherichia coli Infections (1)
Digestive System Diseases (9) · Gastroenteritis (9) · Gastrointestinal Diseases (9) · Intestinal Diseases (9) · Bacterial Infections (8) · Bacterial Infections and Mycoses (8) · Infections (8) · Gram-Negative Bacterial Infections (6) · Enterobacteriaceae Infections (5) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Signs and Symptoms, Digestive (3) · Gram-Positive Bacterial Infections (2) · Clostridium Infections (1)
Rifaximin (1)
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · Assistance Publique - Hôpitaux de Paris (1) · Bausch Health Americas, Inc. (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Genzyme, a Sanofi Company (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Johns Hopkins Bloomberg School of Public Health (1) · Vedanta Biosciences, Inc. (1)
United States (3) · Israel (2) · Mexico (2) · Australia (1) · Bangladesh (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Georgia (1) · Germany (1)
Lin Du (2) · Kawsar Talaat, M.D. (1) · Rachel Schneerson, MD (1) · Swapan Kumar Roy, MBBS, M.Sc, Ph. D (1)
PMID 20412178, PMID 11692292, PMID 12809830, PMID 15017618, PMID 17382603, PMID 17554249, PMID 18809665, PMID 19842970, PMID 20056180, PMID 20086085, PMID 21050319, PMID 21896097, PMID 22864805, PMID 23840001, PMID 29145631